DTIL Precision Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DTIL

Price (delayed)

$0.75

Market cap

$85.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

-$46.19M

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome ...

Highlights
The company's net income has shrunk by 171% YoY but it rose by 2.8% QoQ
DTIL's EPS has dropped by 75% year-on-year but it is up by 10% since the previous quarter
The company's equity fell by 42% YoY and by 34% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://precisionbiosciences.com
Peers: OVID

Key stats

What are the main financial stats of DTIL
Market
Shares outstanding
113.79M
Market cap
$85.35M
Enterprise value
-$46.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.08
Price to sales (P/S)
2.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.51
Earnings
Revenue
$30.56M
EBIT
-$106.94M
EBITDA
-$97.91M
Free cash flow
-$51.37M
Per share
EPS
-$1.14
Free cash flow per share
-$0.46
Book value per share
$0.36
Revenue per share
$0.27
TBVPS
$1.82
Balance sheet
Total assets
$204.5M
Total liabilities
$164.33M
Debt
$26.6M
Equity
$40.18M
Working capital
$122.16M
Liquidity
Debt to equity
0.66
Current ratio
3.61
Quick ratio
3.39
Net debt/EBITDA
1.34
Margins
EBITDA margin
-320.4%
Gross margin
100%
Net margin
-355.1%
Operating margin
-319%
Efficiency
Return on assets
-42.9%
Return on equity
-150.7%
Return on invested capital
-288.6%
Return on capital employed
-67.8%
Return on sales
-349.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DTIL stock price

How has the Precision Biosciences stock price performed over time
Intraday
-2.22%
1 week
1.47%
1 month
-8.54%
1 year
-50.98%
YTD
-36.97%
QTD
-0.48%

Financial performance

How have Precision Biosciences's revenue and profit performed over time
Revenue
$30.56M
Gross profit
$30.56M
Operating income
-$97.48M
Net income
-$108.53M
Gross margin
100%
Net margin
-355.1%
The company's net income has shrunk by 171% YoY but it rose by 2.8% QoQ
DTIL's operating income has shrunk by 103% YoY but it is up by 2.9% QoQ
Precision Biosciences's revenue has plunged by 70% YoY but it has increased by 22% from the previous quarter
Precision Biosciences's gross profit has plunged by 70% YoY but it has increased by 22% from the previous quarter

Growth

What is Precision Biosciences's growth rate over time

Valuation

What is Precision Biosciences stock price valuation
P/E
N/A
P/B
2.08
P/S
2.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.51
DTIL's EPS has dropped by 75% year-on-year but it is up by 10% since the previous quarter
DTIL's P/B is 77% below its 5-year quarterly average of 9.1 but 22% above its last 4 quarters average of 1.7
The company's equity fell by 42% YoY and by 34% QoQ
The P/S is 79% lower than the 5-year quarterly average of 13.1 and 35% lower than the last 4 quarters average of 4.2
Precision Biosciences's revenue has plunged by 70% YoY but it has increased by 22% from the previous quarter

Efficiency

How efficient is Precision Biosciences business performance
The return on invested capital has dropped by 166% year-on-year and by 9% since the previous quarter
Precision Biosciences's ROA has plunged by 127% YoY but it has increased by 5% from the previous quarter
DTIL's ROS is up by 21% since the previous quarter
Precision Biosciences's return on equity has decreased by 7% QoQ

Dividends

What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DTIL.

Financial health

How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 24% more than its total liabilities
The total liabilities is up by 47% year-on-year but it is down by 8% since the previous quarter
DTIL's current ratio is down by 22% year-on-year but it is up by 8% since the previous quarter
DTIL's debt is 34% lower than its equity
The debt to equity has increased by 47% since the previous quarter
The company's equity fell by 42% YoY and by 34% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.